Hone Health offers more than a generic reference to progesterone: its women’s Premium information names compounded oral capsules and gives an estimated medication price. That is a useful starting point. It is also where a reader needs to slow down, because a menu entry is not the full ingredient record and access to medication is not the same as medication included in membership.
Reviewed September 29, 2026, this assessment considers the menopause offer, the Premium care record and a progesterone benefits page. It distinguishes what the capsule entry confirms from the clinical, formulation and financial details it leaves open. No account, consultation, prescription or dispensing transaction was tested.
In this article
The current menu names the capsule and its category
Hone’s Premium membership record explicitly lists Oral Progesterone Capsules as a compound, at an estimated $49 a month. A separate compounded progesterone cream appears at $79 a month. Those are different entries; this review does not treat the cream and capsule as interchangeable or combine them into one product.
The record says medicines require evaluation and clinician approval. It does not identify the capsule’s pharmacy, complete ingredients, exact quantity or manufacturer. Thrivelab’s review examines another preparation list with different detail gaps. A useful comparison preserves what each list actually states, rather than assuming that both providers supply the same capsule because the active hormone is named.
Compounded identifies an approval limit, not an ingredient list
The compounded description in Hone’s menu matters. FDA’s compounding explanation says these medicines are not FDA approved and are not reviewed by the agency for safety, effectiveness and quality before marketing. This is distinct from an approved medicine being prescribed for a use outside its label.
It does not establish the quality of a particular Hone-associated pharmacy or an individual order. Those were not inspected. It does mean that Prometrium’s approval and clinical record cannot be presented as approval of Hone’s unnamed compound. A clinician can explain why the specific preparation is being considered and what evidence supports its intended role.
A broad benefits list is not a general cancer-prevention indication
Hone’s capsule benefits page lists several effects, including an unqualified cancer-prevention statement. That broad wording is not enough to establish that taking its compounded capsule prevents cancer. The page does not identify a cancer type, defined study population or supporting trial for that claim.
The FDA Prometrium label, by comparison, specifies endometrial-hyperplasia prevention for a particular postmenopausal population receiving conjugated estrogen tablets. It is not a general cancer-prevention label and is not the record for Hone’s compound. The medicine-purpose guide keeps that distinction visible. An intended benefit needs a specific clinical explanation rather than the reassurance of a broad list.
Capsule ingredients cannot be borrowed from a familiar brand
The reviewed Premium record does not establish a complete shell or filler list for the oral preparation. An ingredient concern therefore remains open even though the route and compounded category are named. The excipients guide explains why the question belongs to the exact dispensing record.
Peanut oil and a peanut-allergy contraindication appear in the Prometrium label. This review does not assume Hone’s compound contains that oil, nor that it is free of it. The pharmacist should identify the ingredients of the actual prescribed capsule. Substituting a familiar brand’s leaflet would give apparent detail without establishing that it describes the medicine in hand.
The full entry cost has several components
The Premium information describes a $65 initial at-laboratory test, then a $155 monthly membership, with medication charged separately. Follow-up consultations and laboratory work are described as included in that membership. Its estimated medication prices exclude the membership fee and initial testing and may vary with the prescribed treatment.
The menopause page also describes a $25 monthly Basic option, but that is a different access model and should not be substituted for the Premium arrangement just described. Cancellation of Premium takes effect at the end of the current billing period. These published units do not establish the final capsule quantity, a refund entitlement or a personal financial total.
Sleep claims should leave room for an adverse-effect discussion
The capsule benefits page promotes sound sleep while also listing possible adverse effects. The drowsiness guide separates a treatment goal from unwanted daytime impairment. Prometrium’s label warning about dizziness, drowsiness and caution with driving illustrates why exact-product counseling matters; it is not a regimen for Hone’s compound.
Renew Youth’s review examines similar calming-hormone language. Neither provider’s advertised benefit can determine whether a new symptom is acceptable or explain its cause. A reader needs the prescribing team’s guidance for the actual preparation rather than a rule that feeling sleepy proves the medicine is helping.
The useful consultation connects the entry to the person
Hone’s clinical-care description says a physician reviews history and laboratory information and develops a plan. Its promotional timeline should not become a deadline for receiving a capsule or experiencing benefit. A listed medication remains conditional on the clinical assessment and actual availability.
The follow-up guide supports asking who handles changes in symptoms, ingredient questions and prescription issues. Hone’s public record answers one important question—there is a named compounded oral option—but leaves several others unresolved. A complete conversation would explain its role, formulation, price basis and continuing care without presenting the compound as an approved branded product or a universal response to menopause concerns.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- Hone Health: Progesterone Capsule for Women, Risks and BenefitsProvider capsule benefit claims, including an unqualified cancer-prevention statement; reviewed as marketing and limited with exact FDA label context · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- Hone Health: Menopause treatmentProvider menopause service, treatment goals and promotional timeline; not an individual outcome prediction · Checked 2026-09-29